Verastem, Inc.

NASDAQ:VSTM

Biotechnology

Healthcare
$6.87 -0.00%

-$0.00 today

Market cap
$865.72M
Beta
0.27
P/E (TTM)
-2.1
EPS (TTM)
-$1.97
52W Low $3.55High $11.25

Volume 3.97M

Average 2.58M

VSTM Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Verastem, Inc.NASDAQ: VSTM

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was $15.62M, compared with $0 a year earlier. Trailing-twelve-month gross profit was $41.53M. Over 3 fiscal years it compounded at +114.5% a year.

Context

  • Gross profit amounted to 82.9% of revenue in FY2025, down 17.1 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $15.62M or moves back toward the trailing-twelve-month quarterly average of $10.38M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.62M+6.7% QoQ
Last fiscal yearDec 2025
$25.62M+156.2% YoY
LTMMar 2026
$41.53M+315.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+156.2%——
3-year CAGR+114.5%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
25.62M USD
Year-over-year change
+156.2%
4-year CAGR
+87.9%

Gross Profit vs competitors

How VSTM compares with its peers on the latest reported figures

  • VSTM's LTM Mar 2026 gross profit of $41.53M is the 2nd highest of the 11 companies compared; the peer median is $3.26M.
  • Its year-over-year change of +315.3% is the 2nd highest of 10, against a peer median of -5.3%.
  • Gross profit amounts to 83.7% of revenue for VSTM, versus a peer median of 96.2%.
VSTM Competitors Peer median
Gross Profit for VSTM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NUVBNuvation Bio Inc.LTM Jun 2026$159.6M +3936.4%—93.9%
VSTMVerastem, Inc.LTM Mar 2026$41.53M +315.3%+114.5%83.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$33.06M -2.5%-3.5%94.8%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$16.33M +133.3%—97.7%
ANLAdlai Nortye Ltd.LTM Jun 2024$6.49M ——100.0%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$6.28M -73.3%+12.8%22.3%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$228K +137.1%——
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026-$186K -19.2%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026-$320K -5.3%——
IMRXImmuneering CorporationLTM Mar 2026-$793.21K -354.2%——
CRDFCardiff Oncology, Inc.LTM Mar 2026-$11.06M -20.7%+15.4%2105.7%
Peer median (excluding VSTM) $3.26M-5.3%+12.8%96.2%

Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.05M2.6M010M30.91M
Cost of Revenue00005.3M
Gross Profit2.05M2.6M010M25.62M
Gross Margin100.0%100.0%—100.0%82.9%
Research & Development39.35M50.56M61.36M81.33M114.6M
Selling, General & Admin24.12M24.98M30.73M43.62M81.15M
Operating Expenses63.46M75.53M92.08M124.96M195.75M
Depreciation & Amortization72K118K62K26K728K
EBITDA(61.16M)(71.56M)(83.17M)(125.86M)(207.61M)
EBITDA Margin-2978.9%-2756.4%—-1258.6%-671.6%
Operating Income(61.41M)(72.94M)(92.08M)(114.96M)(170.13M)
Operating Margin-2991.2%-2809.6%—-1149.6%-550.3%
Interest Income181K1.22M6.21M4.15M4.07M
Interest Expense9.97M2.14M4.14M4.56M1.14M
Other Income / Expenses(9.79M)(875K)4.72M(15.5M)(39.34M)
Income Before Tax(71.2M)(73.81M)(87.37M)(130.45M)(209.47M)
Pre-Tax Margin-3468.1%-2843.3%—-1304.5%-677.6%
Income Tax Expense000185K0
Net Income(71.2M)(73.81M)(87.37M)(130.64M)(209.47M)
Net Margin-3468.1%-2843.3%—-1306.4%-677.6%
EPS (Basic)(4.92)(4.57)(3.96)(3.66)(3.02)
EPS (Diluted)(4.92)(4.57)(3.96)(3.66)(3.02)
Weighted Avg Shares14.53M16.14M22.05M35.71M69.31M
Weighted Avg Shares (Diluted)14.53M16.14M22.05M35.71M69.31M

Verastem, Inc.

NASDAQ:VSTM

Intrinsic Alpha fair value

Locked

Current Price

$6.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.